Bristol Myers Squibb management check
BMY · Health Care · Pharmaceuticals · CEO Christopher S. Boerner
Filings as of
Closest peers in Pharmaceuticals
- 35LLYLilly (Eli)84
- 181JNJJohnson & Johnson70
- 195ZTSZoetis68
- 261MRKMerck & Co.64
- 277PFEPfizer63
- 335BMYBristol Myers Squibb59
- 369VTRSViatris57
The seven checks
- FlagTrailed its chosen peers
Have owners done well?
What $100 became since fiscal 2021
016thDetail
$100 invested at the start of fiscal 2021 grew to $105, against $198 for the peer group the company picked itself.
- GoodPay rose and fell with returns
Does pay follow performance?
Pay actually paid $100 value, each on its own scale
9996thDetail
Over 5 years, the CEO's pay actually paid (equity valued at the share price) had a correlation of 0.98 with shareholder return. 1 means pay moved in step; below 0, the opposite way.
- Good0.3% of net income
What does the CEO cost owners?
$21.9m pay · $7.1bn net income, FY2025
9288thDetail
$21.9m of reported pay in fiscal 2025, against $7.1bn of net income.
- WatchCEO stake ≈ 0.1 years of pay
Do they own the stock?
24,821 shares ≈ $1.6m
6 mo: ▲ $0 bought · ▼ $678k sold
05thDetail
The CEO holds 24,821 shares, directly or through trusts (unvested awards not counted): about 0.1 years of pay. Light activity: no buys, $678k sold in six months.
- GoodShare count shrinking
Are owners being diluted?
Diluted shares −0.9% a year; flagged above +2%
Stock pay 1.1% of revenue
6252ndDetail
Diluted shares changed -0.9% a year over the last three fiscal years. Stock-based pay was 1.1% of revenue in the latest year.
- Watch2 CEOs in the pay table
Is leadership stable?
5 filings under 8-K 5.02 in 3 years
CEOs: Dr. Giovanni Caforio, Dr. Chris Boerner
6038thDetail
CEOs in the pay table: Dr. Giovanni Caforio, Dr. Chris Boerner. 5 filings under 8-K item 5.02 (officers or directors leaving or joining, or new pay arrangements) in the last 3 years.
- GoodNo red flags on file
Are the books clean?
Since 2021
- 0Restated
- 0Auditor changes
- 0Late filings
- 010-K amended
100100thDetail
No restatements, auditor changes or late filings since 2021.
Reading the scores
Each check scored 0–100 from its own figure. The tick is the Health Care median; the ordinal is the share of ranked S&P 500 companies it matches or beats.
Hover a chart for its figures. Detail has the full reading.
Pay versus performance
From the proxy statement filed March 25, 2026.
Pay tied most to total revenues
Other key measuresRevenueSSI ScorecardPipelineStock PriceOperating IncomeRelative TSR
Show the figures
| Fiscal year | CEO | CEO pay | Actually paid | Other executives (avg) | $100 became | Peers | Net income |
|---|---|---|---|---|---|---|---|
| 2025 | Dr. Chris Boerner | $21.9m | $16.9m | $9.2m | $105 | $198 | $7.1bn |
| 2024 | Dr. Chris Boerner | $18.8m | $21.2m | $7.7m | $105 | $154 | −$8.9bn |
| 2023 | Dr. Giovanni Caforio | $19.7m | $383k | $5.9m | $91 | $142 | $8.0bn |
| 2022 | Dr. Giovanni Caforio | $20.1m | $35.1m | $7.0m | $123 | $139 | $6.3bn |
| 2021 | Dr. Giovanni Caforio | $19.8m | $16.5m | $7.1m | $103 | $126 | $7.0bn |
Insiders and the CEO's stakeQuiet
- Chief Executive Officer
- Christopher S. Boerner
- Shares held
- 24,821
- At that filing's price
- ≈ $1.6m
- Latest Form 4
- Nov 1, 2026
Light activity: no buys, $678k sold in six months.
Open-market trades by officers and directors since May 21, 2026.
- SoldCristian MassacesiEVP,Chief Med Offr,Head of Dev$403kSep 9, 2026
- SoldJulia A HallerDirector$241kNov 5, 2026
- SoldPhil M HolzerSVP and Controller$34kAug 25, 2026
Leadership and governance on file
All 11 filings
- Jul 25, 2025Leadership change8-K 5.02
- Feb 18, 2025Leadership change8-K 5.02
- Jun 18, 2024Leadership change8-K 5.02
- Mar 18, 2024Leadership change8-K 5.02
- Feb 15, 2024Leadership change8-K 5.02
- Oct 31, 2023Leadership change8-K/A 5.02
- May 4, 2023Leadership change8-K 5.02
- Apr 26, 2023Leadership change8-K 5.02
- Jan 31, 2023Leadership change8-K 5.02
- Jun 15, 2022Leadership change8-K 5.02
- Mar 17, 2022Leadership change8-K 5.02
Latest shareholder vote results: May 8, 2026, including the say-on-pay vote.
Where the money went
2021–2025: $43.1bn returned to owners in buybacks and dividends, 222% of net income, and $2.6bn of pay in stock.
Show the figures
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $46.4bn | $46.2bn | $45.0bn | $48.3bn | $48.2bn |
| Net income | $7.0bn | $6.3bn | $8.0bn | −$8.9bn | $7.1bn |
| Stock-based pay | $583.0m | $457.0m | $518.0m | $507.0m | $553.0m |
| Buybacks | $6.3bn | $8.0bn | $5.2bn | $0 | $0 |
| Dividends | $4.4bn | $4.6bn | $4.7bn | $4.9bn | $5.0bn |
| Diluted shares | 2245m | 2146m | 2078m | 2027m | 2039m |
Educational only, not investment advice. Figures are as filed with the SEC: pay from the proxy's pay-versus-performance table, capital allocation from 10-K XBRL data, insider trades from Form 4s over the last six months, events from the last 5 years of filings. The peer group is the one the company chose. See the method.